PMID- 30709557
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20200910
IS  - 1535-6345 (Electronic)
IS  - 0147-0272 (Linking)
VI  - 43
IP  - 6
DP  - 2019 Dec
TI  - Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment 
      for multiple-day anthracycline-induced nausea and vomiting.
PG  - 100462
LID - S0147-0272(18)30379-9 [pii]
LID - 10.1016/j.currproblcancer.2019.01.003 [doi]
AB  - OBJECTIVE: To assess the safety and efficacy of combined neurokinin-1 antagonist 
      aprepitant treatment for multiple-day anthracycline chemotherapy-induced nausea 
      and vomiting. METHODS: One hundred patients with breast cancer from department of 
      Medical Oncology of Ordos Central Hospital from June 2015 to February 2018 were 
      selected and randomize subdivided into 2 groups. All cases received anthracycline 
      (30 mg/m(2)/d for pirarubicin or 45 mg/m(2)/d for epirubicin) and 
      cyclophosphamide adjuvant chemotherapy, along with either the standard therapy 
      (dexamethasone and tropisetron) or the combined aprepitant therapy (aprepitant 
      plus dexamethasone and tropisetron). The results of the observation between 
      groups were presented by complete response in the overall phase (OP, 0-120 
      hours), acute phase (AP, 0-24 hours) and delay phase (DP, 25-120 hours). The 
      Kaplan-Meier curves were plotted to exhibit the first time of vomiting, 
      Functional Living Index-Emesis of patients' quality of life, and therapy-related 
      adverse effects (AEs). RESULTS: The complete response of OP, AP, and DP were 
      statistically different between aprepitant group and standard group (80.0% vs 
      48%, P = 0.001; 92.0% vs 74%, P = 0.017; 80.0% vs 48%, P = 0.001). The aprepitant 
      group held a longer time reaching the first emesis after the relevant treatment 
      than the standard group. The Functional Living Index-Emesis increased 
      significantly in the aprepitant group compared with the standard group (24% vs 
      8.3%, P = 0.029). Fatigue and constipation were the only AEs of aprepitant, since 
      no significant differences were observed in fatigue between the 2 groups (72% vs 
      70%, P = 0.826), while the incidence of constipation of aprepitant group was 
      higher than the standard group (48% vs 28%, P = 0.039). CONCLUSION: Combined 
      aprepitant therapy is efficient and safe in the multiple-day anthracycline 
      chemotherapy-induced nausea and vomiting control and is recommended for the 
      clinical use.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Li, Quanfu
AU  - Li Q
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Wu, Yungaowa
AU  - Wu Y
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Wang, Wenjuan
AU  - Wang W
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Deng, Shuqin
AU  - Deng S
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Jiang, Caihong
AU  - Jiang C
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Chen, Feng
AU  - Chen F
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Zhao, Jun
AU  - Zhao J
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Li, Hui
AU  - Li H
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Bai, Xiaojun
AU  - Bai X
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Hou, Jixiang
AU  - Hou J
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Da, Lenggaowa
AU  - Da L
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Zhao, Lanzhen
AU  - Zhao L
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Gao, Jiali
AU  - Gao J
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia.
FAU - Jin, Gaowa
AU  - Jin G
AD  - Department of Medical Oncology, Ordos Central Hospital, Ordos, Mongolia. 
      Electronic address: jingaowank@163.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20190123
PL  - United States
TA  - Curr Probl Cancer
JT  - Current problems in cancer
JID - 7702986
RN  - 0 (Neurokinin-1 Receptor Antagonists)
RN  - 1NF15YR6UY (Aprepitant)
RN  - 3Z8479ZZ5X (Epirubicin)
RN  - 80168379AG (Doxorubicin)
RN  - D58G680W0G (pirarubicin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects
MH  - Aprepitant/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Case-Control Studies
MH  - Doxorubicin/administration & dosage/analogs & derivatives
MH  - Epirubicin/administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Middle Aged
MH  - Nausea/chemically induced/*drug therapy/pathology
MH  - Neurokinin-1 Receptor Antagonists/*therapeutic use
MH  - Prognosis
MH  - Prospective Studies
MH  - Survival Rate
MH  - Vomiting/chemically induced/*drug therapy/pathology
OTO - NOTNLM
OT  - Anthracycline
OT  - Aprepitant
OT  - CINV
OT  - Multiple-day chemotherapy
EDAT- 2019/02/03 06:00
MHDA- 2020/09/12 06:00
CRDT- 2019/02/03 06:00
PHST- 2018/11/14 00:00 [received]
PHST- 2019/01/10 00:00 [accepted]
PHST- 2019/02/03 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2019/02/03 06:00 [entrez]
AID - S0147-0272(18)30379-9 [pii]
AID - 10.1016/j.currproblcancer.2019.01.003 [doi]
PST - ppublish
SO  - Curr Probl Cancer. 2019 Dec;43(6):100462. doi: 
      10.1016/j.currproblcancer.2019.01.003. Epub 2019 Jan 23.